Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
256,634
-
Share change
-
-44,853
-
Total reported value
-
$406,818
-
Put/Call ratio
-
19%
-
Price per share
-
$1.58
-
Number of holders
-
15
-
Value change
-
-$97,129
-
Number of buys
-
2
-
Number of sells
-
8
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q3 2023
As of 30 Sep 2023,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
256,634 shares.
The largest 10 holders included
Compagnie Lombard Odier SCmA, RENAISSANCE TECHNOLOGIES LLC, MORGAN STANLEY, CITADEL ADVISORS LLC, EDMOND DE ROTHSCHILD HOLDING S.A., Susquehanna International Group Ltd., GEODE CAPITAL MANAGEMENT, LLC, WELLS FARGO & COMPANY/MN, Steward Partners Investment Advisory, LLC, and JPMORGAN CHASE & CO.
This page lists
14
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.